vigiRank is a data-driven predictive model for emerging safety signals. In addition to disproportionate reporting patterns, it also accounts for the completeness, recency, and geographic spread of individual case reporting, as well as the availability of case narratives. Previous retrospective analysis suggested that vigiRank performed better than disproportionality analysis alone.
Watson S, Chandler R, Taavola H, et al. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre. Drug Saf. September 2017. [PubMed]
Caster O, Juhlin K, Watson S, Norén G. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank. Drug Saf. 2014;37(8):617-628. [PubMed]
Caster O, Sandberg L, Bergvall T, Watson S, Norén G. vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use. Pharmacoepidemiol Drug Saf. 2017;26(8):1006-1010. [PubMed]
Bergvall T, Norén G, Lindquist M. vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf. 2014;37(1):65-77. [PubMed]